title: [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
authors.affiliation: Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. itopapa@intmed3.kysushu-u.ac.jp
authors.forename: Tetsuhide
authors.initials: T
authors.lastname: Ito
authors.forename: Hisato
authors.initials: H
authors.lastname: Igarashi
authors.forename: Robert T
authors.initials: RT
authors.lastname: Jensen
authors.forename: Ryoichi
authors.initials: R
authors.lastname: Takayanagi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013505:Digestive System Surgical Procedures; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D058990:Molecular Targeted Therapy; D018358:Neuroendocrine Tumors / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D011758:Pyrroles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D013311:Streptozocin / Q000627:therapeutic use; D000077210:Sunitinib; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D007211:Indoles; D011758:Pyrroles; D013004:Somatostatin; D013311:Streptozocin; D003606:Dacarbazine; C517782:pasireotide; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus; D000077204:Temozolomide